MNKDMannKind Corporation
Price
-39%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, demanding price, growth steady, the market undecided.
We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
MannKind Corporation (MNKD) reported revenue of $109M in Q2 2026 (quarter ended Jun 30, 2026), up 43% from the same quarter a year earlier. That came with a gross margin of 87% and net loss of $19M. For the full year FY2025, revenue was $349M (+22% year on year) and net income $5.9M. Its largest product in Q2 2026 was Product at $72M, 62% of the disclosed total, well ahead of Furoscix at 19%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 21, 2026On August 21, 2026, MannKind Corporation (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the Securities and Exchange Commission.Other event · Form 8-K
- Aug 5, 2026MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jul 24, 2026On July 23, 2026, the U.S. Food and Drug Administration approved Furoscix ReadyFlow ™ (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease.Unregistered sale of equity · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $116.0MThe company’s own SEC segment disclosure.
- Product$71.6M62%
- Furoscix$22.2M19%
- Afrezza$17.0M15%
- V Go$2.8M2%
- Manufacturing Services$2.4M2%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.